Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an epilepsy drug tipped as a future blockbuster. The Danish drugmaker has ...

Longboard's 5-HT 2C receptor super-agonist ... down part of the book value of its $400 million acquisition of Abide Therapeutics in 2018 after the failure of an early-stage candidate, but said ...